Abstract
Background: Deep vein thrombosis (DVT) management remains challenging despite standard anticoagulation therapy. This study evaluated the comprehensive benefits of combining rivaroxaban with Aescuven (CAV) compared to rivaroxaban monotherapy (SAT) in DVT treatment. Methods: A retrospective analysis was conducted on DVT patients (2018-2023) using multi-method propensity score matching and ensemble weighting. Outcomes included improvement rate (IPR), daily improvement rate (DIR), cost-effectiveness ratio (CER), daily improvement cost (DIC), cost-LOS efficiency (CLE), and length of stay (LOS). Counterfactual analysis was implemented to estimate causal effects. Results: The CAV group demonstrated superior outcomes compared to SAT: IPR increased by 6.39 percentage points (95% CI: 5.61-7.39), DIC substantially reduced by 3323.38 CNY (95% CI: 2887.95-3758.81), and CLE improved by 136.97 CNY per day (95% CI: 122.31-151.64), with minimal LOS increase (0.15 days, 95% CI: 0.12-0.18). Network analysis revealed significant correlations between baseline coagulation parameters and treatment outcomes, particularly between APTT and economic benefits. Conclusions: The CAV regimen achieved significant clinical and economic advantages over standard monotherapy without substantially increasing resource utilization. These findings support integrating venoprotective agents into conventional anticoagulation strategies for optimized DVT management.